18F-Florastamin PSMA PET/CT 在疑似中危前列腺癌患者中的诊断准确性
本研究前瞻性纳入59例疑似中危前列腺癌(前列腺特异性抗原3-20 ng/mL)患者,均行18F-Florastamin PSMA PET/CT与多参数磁共振成像(mpMRI),以前列腺活检为参考标准。PSMA PET/CT灵敏度72.4%、特异度83.3%、准确率78%,mpMRI灵敏度89.7%、特异度66.7%、准确率78%,两者AUC均为0.78(P=0.967)。作者认为PSMA PET/CT诊断准确性与mpMRI相当,且特异度更高。
要点
- PSMA PET/CT灵敏度72.4%、特异度83.3%、准确率78%,AUC 0.78(95%CI 0.67-0.89)。
- mpMRI灵敏度89.7%、特异度66.7%、准确率78%,AUC 0.78(95%CI 0.68-0.88)。
- 两者AUC差异无统计学意义(P=0.967),PSMA PET/CT特异度与阳性预测值更高。
核心结论
- 18F-Florastamin PSMA PET/CT的诊断准确性与mpMRI相当,并具有更高特异度的额外优势。
- 作者认为PSMA PET/CT可补充mpMRI用于中危前列腺癌的诊断评估,有助于患者分层并辅助临床决策。
研究设计与样本
- 前瞻性研究,纳入59例疑似中危前列腺癌患者,前列腺特异性抗原3-20 ng/mL。
- 所有参与者均接受18F-Florastamin PSMA PET/CT与mpMRI检查,分别采用PSMA-Reporting and Data System与前列腺影像报告和数据系统第2.1版评分。
- 以前列腺活检为参考标准,计算灵敏度、特异度、阳性预测值、阴性预测值、准确率及受试者工作特征曲线下面积(AUC)以比较两种 modality。
主要发现
- PSMA PET/CT灵敏度72.4%、特异度83.3%、总准确率78%,AUC 0.78(95%CI 0.67-0.89)。
- mpMRI灵敏度89.7%、特异度66.7%、总准确率78%,AUC 0.78(95%CI 0.68-0.88)。
- 两种方法AUC差异无统计学意义(P=0.967)。
- PSMA PET/CT特异度与阳性预测值更高,减少假阳性结果;mpMRI在灵敏度与阴性预测值方面更优,减少假阴性。
关键数值与推荐
- PSMA PET/CT:灵敏度72.4%、特异度83.3%、准确率78%、AUC 0.78(95%CI 0.67-0.89)。
- mpMRI:灵敏度89.7%、特异度66.7%、准确率78%、AUC 0.78(95%CI 0.68-0.88)。
- 两种方法AUC比较P=0.967。
临床怎么用
- 作者认为PSMA PET/CT可补充mpMRI用于中危前列腺癌的诊断评估,有助于患者分层并辅助临床决策。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: This study aimed to evaluate the diagnostic accuracy of 18F-Florastamin prostate-specific membrane antigen (PSMA) positron emission tomography-computed tomography (PET/CT) in detecting intermediate-risk prostate cancer and compare its performance with multiparametric magnetic resonance imaging (mpMRI). PATIENTS AND METHODS: Fifty-nine patients with suspected intermediate-risk prostate cancer (prostate-specific antigen: 3-20 ng/mL) were prospectively enrolled. All participants underwent examination with 18F-Florastamin PET/CT and mpMRI, with imaging results assessed using the PSMA-Reporting and Data System and Prostate Imaging-Reporting and Data System Version 2.1 scoring systems, respectively. Prostate biopsy served as the reference standard. Diagnostic metrics, including sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV), accuracy, and area under the receiver operating characteristic curve (AUC), were calculated to compare the 2 modalities. RESULTS: PSMA PET/CT demonstrated a sensitivity of 72.4%, specificity of 83.3%, and overall accuracy of 78%, with an AUC of 0.78 (95% CI: 0.67-0.89). Contrastingly, mpMRI showed a higher sensitivity (89.7%) but lower specificity (66.7%), achieving the same overall accuracy of 78% and an AUC of 0.78 (95% CI: 0.68-0.88). No statistically significant difference in AUC was observed between the 2 modalities (P=0.967). While PSMA PET/CT offered higher specificity and PPV, reducing false-positive results, mpMRI excelled in sensitivity and NPV, minimizing false negatives. CONCLUSIONS: 18F-Florastamin PSMA PET/CT demonstrated comparable diagnostic accuracy to mpMRI, with the added benefit of higher specificity. These findings suggest that PSMA PET/CT could complement mpMRI in the diagnostic evaluation of intermediate-risk prostate cancer, enhancing patient stratification and aiding clinical decision-making.
引用
- Yuei J, Jung W, Won KS, et al. Diagnostic Accuracy of PSMA-targeted 18F-Florastamin PET/CT in Intermediate-risk Patients With Suspected Prostate Cancer. Clin Nucl Med. 2025. PMID: 40320630. doi:10.1097/RLU.0000000000005798
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。